In vitro emergence of high persistence upon periodic aminoglycoside challenge in the ESKAPE pathogens

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4630-4637

  Michiels, Joran Elie ^a   Van Den Bergh, Bram ^a   Verstraeten, Natalie ^a   Fauvart, Maarten ^a,b   Michiels, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b IMEC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERSISTENCE; BACTERIAL PHENOMENA AND FUNCTIONS; BIOFILM; CATALYST; CONTROLLED STUDY; CROSS TOLERANCE; ENTEROBACTER AEROGENES; ENTEROCOCCUS FAECIUM; GENETIC RESISTANCE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTER; HUMAN; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOFILMS; CROSS INFECTION; ENTEROBACTER; ENTEROCOCCUS FAECIUM; HUMANS; KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84979270630     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00757-16     Document Type: Article

References (59)

1. World Health Organization. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland.
2. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1081. http://dx.doi.org/10.1086/533452.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
4. Pendleton JN, Gorman SP, Gilmore BF. 2013. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11:297-308. http://dx.doi.org/10.1586/eri.13.12.
5. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. 2014. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370: 1198-1208. http://dx.doi.org/10.1056/NEJMoa1306801.
6. Bassetti M, Merelli M, Temperoni C, Astilean A. 2013. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:12-22. http://dx.doi.org/10.1186/1476-0711-12-12.
7. Tommasi R, Brown DG, Walkup GK, Manchester JI, Miller AA. 2015. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14:529-542. http://dx.doi.org/10.1038/nrd4572.
8. O'Neill J. 2014. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. In Review on antimicrobial resistance. Government of the United Kingdom, London, United Kingdom.
9. Lewis K. 2010. Persister cells. Annu Rev Microbiol 64:357-372. http://dx.doi.org/10.1146/annurev.micro.112408.134306.
10. Fauvart M, De Groote VN, Michiels J. 2011. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 60:699-709. http://dx.doi.org/10.1099/jmm.0.030932-0.
11. Claudi B, Spröte P, Chirkova A, Personnic N, Zankl J, Schürmann N, Schmidt A, Bumann D. 2014. Phenotypic variation of Salmonella in host tissues delays eradication by antimicrobial chemotherapy. Cell 158:722-733. http://dx.doi.org/10.1016/j.cell.2014.06.045.
12. Kaiser P, Regoes RR, Dolowschiak T, Wotzka SY, Lengefeld J, Slack E, Grant AJ, Ackermann M, Hardt W-D. 2014. Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment. PLoS Biol 12:e1001793. http://dx.doi.org/10.1371/journal.pbio.1001793.
13. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5:48-56. http://dx.doi.org/10.1038/nrmicro1557.
14. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190-1196. http://dx.doi.org/10.1086/314727.
15. Mulcahy LR, Burns JL, Lory S, Lewis K. 2010. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192:6191-6199. http://dx.doi.org/10.1128/JB.01651-09.
16. Grant SS, Hung DT. 2013. Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence 4:273-283. http://dx.doi.org/10.4161/viru.23987.
17. Donlan RM. 2001. Biofilms and device-associated infections. Emerg Infect Dis 7:277-281. http://dx.doi.org/10.3201/eid0702.010226.
18. Siddiqui AR, Bernstein JM. 2010. Chronic wound infection: facts and controversies. Clin Dermatol 28:519-526. http://dx.doi.org/10.1016/j.clindermatol.2010.03.009.
19. Levin BR, Rozen DE. 2006. Non-inherited antibiotic resistance. Nat Rev Microbiol 4:556-562. http://dx.doi.org/10.1038/nrmicro1445.
20. Cohen NR, Lobritz MA, Collins JJ. 2013. Microbial persistence and the road to drug resistance. Cell Host Microbe 13:632-642. http://dx.doi.org/10.1016/j.chom.2013.05.009.
21. Maisonneuve E, Gerdes K. 2014. Molecular mechanisms underlying bacterial persisters. Cell 157:539-548. http://dx.doi.org/10.1016/j.cell.2014.02.050.
22. Verstraeten N, Knapen WJ, Kint CI, Liebens V, Van den Bergh B, Dewachter L, Michiels JE, Fu Q, David CC, Fierro CA, Marchal K, Beirlant J, Versées W, Hofkens J, Jansen M, Fauvart M, Michiels J. 2015. Obg and membrane depolarization are part of a microbial bethedging strategy that leads to antibiotic tolerance. Mol Cell 59:9-21. http://dx.doi.org/10.1016/j.molcel.2015.05.011.
23. Helaine S, Kugelberg E. 2014. Bacterial persisters: formation, eradication, and experimental systems. Trends Microbiol 22:417-424. http://dx.doi.org/10.1016/j.tim.2014.03.008.
24. Maisonneuve E, Castro-Camargo M, Gerdes K. 2013. (p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity. Cell 154:1140-1150. http://dx.doi.org/10.1016/j.cell.2013.07.048.
25. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK. 2011. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334:982-986. http://dx.doi.org/10.1126/science.1211037.
26. Helaine S, Cheverton AM, Watson KG, Faure LM, Matthews SA, Holden DW. 2014. Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science 343:204-208. http://dx.doi.org/10.1126/science.1244705.
27. Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, Clair G, Adkins JN, Cheung AL, Lewis K. 2016. Persister formation in Staphylococcus aureus is associated with ATP depletion. Nat Microbiol 1:16051. http://dx.doi.org/10.1038/nmicrobiol.2016.51.
28. Balaban NQ, Gerdes K, Lewis K, McKinney JD. 2013. A problem of persistence: still more questions than answers? Nat Rev Microbiol 11:587-591. http://dx.doi.org/10.1038/nrmicro3076.
29. Poulikakos P, Falagas ME. 2013. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother 14:1585-1597. http://dx.doi.org/10.1517/14656566.2013.806486.
30. Van den Bergh B, Michiels JE, Wenseleers T, Windels EM, Vanden Boer P, Kestemont D, De Meester L, Verstrepen KJ, Verstraeten N, Fauvart M, Michiels J. 2016. Frequency of antibiotic application drives rapid evolutionary adaptation of Escherichia coli persistence. Nat Microbiol 1:16020. http://dx.doi.org/10.1038/nmicrobiol.2016.20.
31. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776.
32. O'Toole GA. 2011. Microtiter dish biofilm formation assay. J Vis Exp 47:e2437. http://dx.doi.org/10.3791/2437.
33. Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48:5-16. http://dx.doi.org/10.1093/jac/48.suppl-1.5.
34. Van den Bergh B, Michiels JE, Michiels J. 2016. Experimental evolution of Escherichia coli persister levels using cyclic antibiotic treatments, p 131-143. In Methods in molecular biology. Springer Science, New York, NY.
35. Fux CA, Costerton JW, Stewart PS, Stoodley P. 2005. Survival strategies of infectious biofilms. Trends Microbiol 13:34-40. http://dx.doi.org/10.1016/j.tim.2004.11.010.
36. Conlon BP, Nakayasu ES, Fleck LE, Lafleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503:365-370. http://dx.doi.org/10.1038/nature12790.
37. Keren I, Kaldalu N, Spoering AL, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230:13-18. http://dx.doi.org/10.1016/S0378-1097(03)00856-5.
38. Stankowicz MS, Ibrahim J, Brown DL. 2015. Once-daily aminoglycoside dosing: an update on current literature. Am J Health Syst Pharm 72:1357-1364. http://dx.doi.org/10.2146/ajhp140564.
39. Kussell E, Kishony R, Balaban NQ, Leibler S. 2005. Bacterial persistence: a model of survival in changing environments. Genetics 169:1807-1814. http://dx.doi.org/10.1534/genetics.104.035352.
40. Wiuff C, Zappala R, Regoes RR, Garner K, Baquero F, Levin BR. 2005. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49:1438-1494.
41. Putrinš M, Kogermann K, Lukk E, Lippus M, Varik V, Tenson T. 2015. Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement. Infect Immun 83:1056-1067. http://dx.doi.org/10.1128/IAI.02725-14.
42. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
43. De Groote VN, Verstraeten N, Fauvart M, Kint CI, Verbeeck AM, Beullens S, Cornelis P, Michiels J. 2009. Novel persistence genes in Pseudomonas aeruginosa identified by high-throughput screening. FEMS Microbiol Lett 297:73-79. http://dx.doi.org/10.1111/j.1574-6968.2009.01657.x.
44. Johnson PJT, Levin BR. 2013. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet 9:e1003123. http://dx.doi.org/10.1371/journal.pgen.1003123.
45. Barth VC, Rodrigues BÁ Bonatto GD, Gallo SW, Pagnussatti VE, Ferreira CAS, de Oliveira SD. 2013. Heterogeneous persister cells formation in Acinetobacter baumannii. PLoS One 8:e84361. http://dx.doi.org/10.1371/journal.pone.0084361.
46. Bhargava N, Sharma P, Capalash N. 2014. Pyocyanin stimulates quorum sensing-mediated tolerance to oxidative stress and increases persister cell populations in Acinetobacter baumannii. Infect Immun 8:3417-3425. http://dx.doi.org/10.1128/IAI.01600-14.
47. Ren H, He X, Zou X, Wang G, Li S, Wu Y. 2015. Gradual increase in antibiotic concentration affects persistence of Klebsiella pneumoniae. J Antimicrob Chemother 70:3267-3272. http://dx.doi.org/10.1093/jac/dkv251.
48. Roger C, Nucci B, Molinari N, Bastide S, Saissi G, Pradel G, Barbar S, Aubert C, Lloret S, Elotmani L, Polge A, Lefrant J-Y, Roberts JA, Muller L. 2015. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents 46:21-27. http://dx.doi.org/10.1016/j.ijantimicag.2015.02.009.
49. Quon BS, Goss CH, Ramsey BW. 2014. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 11:425-434. http://dx.doi.org/10.1513/AnnalsATS.201311-395FR.
50. Fridman O, Goldberg A, Ronin I, Shoresh N, Balaban NQ. 2014. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature 99:418-421. http://dx.doi.org/10.1038/nature13469.
51. Mechler L, Herbig A, Paprotka K, Fraunholz M, Nieselt K, Bertram R. 2015. A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus. Antimicrob Agents Chemother 59:5366-5376. http://dx.doi.org/10.1128/AAC.00643-15.
52. Goneau LW, Yeoh NS, Macdonald KW, Cadieux PA, Burton JP, Razvi H, Reid G. 2014. Selective target inactivation rather than global metabolic dormancy causes antibiotic tolerance in uropathogens. Antimicrob Agents Chemother 58:2089-2097. http://dx.doi.org/10.1128/AAC.02552-13.
53. LaFleur MD, Qi Q, Lewis K. 2010. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 54:39-44. http://dx.doi.org/10.1128/AAC.00860-09.
54. Van Acker H, Sass A, Bazzini S, De Roy K, Udine C, Messiaen T, Riccardi G, Boon N, Nelis HJ, Mahenthiralingam E, Coenye T. 2013. Biofilm-grown Burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species. PLoS One 8:e58943. http://dx.doi.org/10.1371/journal.pone.0058943.
55. Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgo{combining double acute accent} B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. 2013. Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol 9:700. http://dx.doi.org/10.1038/msb.2013.57.
56. Allison KR, Brynildsen MP, Collins JJ. 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473:216-220. http://dx.doi.org/10.1038/nature10069.
57. Percival SL, Suleman L, Vuotto C, Donelli G. 2015. Healthcareassociated infections, medical devices and biofilms: risk, tolerance and control. J Med Microbiol 64(Pt 4):323-334. http://dx.doi.org/10.1099/jmm.0.000032.
58. Mok WWK, Orman MA, Brynildsen MP. 2015. Impacts of global transcriptional regulators on persister metabolism. Antimicrob Agents Chemother 59:2713-2719. http://dx.doi.org/10.1128/AAC.04908-14.
59. Shan Y, Lazinski D, Rowe S, Camilli A, Lewis K. 2015. Genetic basis of persister tolerance to aminoglycosides in Escherichia coli. mBio 6:e000078-15. http://dx.doi.org/10.1128/mBio.00078-15.